培土滋肾方联合免疫疗法治疗晚期非小细胞肺癌的临床疗效

目的 探讨培土滋肾方联合免疫疗法治疗晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）患者的临床疗效。方法 选取2019年1月至2021年1月于临海市中医院治疗的晚期NSCLC患者100例,根据随机数字表法将其分为研究组和对照组,每组各50例。对照组患者予帕博利珠单抗治疗,研究组患者在对照组的基础上予培土滋肾方治疗。两组均治疗10个疗程。比较两组患者的临床疗效、中医证候积分、循环肿瘤细胞（circulating tumor cell,CTC）、程序性死亡蛋白配体1（programmed death-ligand 1,PD-L1）水平及不良反应发生情况。结果 治疗后,两组患者的客观缓解率和疾病控制率比较差异均无统计学意义（P>0.05）。治疗后,研究组患者的咳嗽、咳痰、胸闷气短、胸痛中医证候积分与CTC和PD-L1水平均显著低于对照组（P<0.05）;研究组患者的贫血、胃肠道不良反应、肾功能损害发生率均显著低于对照组（P<0.05）。结论 培土滋肾方联合免疫疗法可改善晚期NSCLC患者的中医证候积分,降低患者的CTC、PD-L1水平及贫...

Clinical effect of Peitu Zishen decoction combined with immunotherapy in the treatment of advanced non-small cell lung cancer

Objective To explore the clinical effect of Peitu Zishen decoction combined with immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 100 patients with advanced NSCLC treated in Linhai Hospital of Traditional Chinese Medicine from January 2019 to January 2021 were selected and divided into study group and control group according to random number table method, with 50 cases in each group. The control group was treated with pembrolizumab, and the study group was treated with Peitu Zishen decoction on the basis of the control group. Both groups were treated for 10 courses. The clinical efficacy, TCM syndrome scores, circulating tumor cell (CTC), programmed death-ligand 1 (PD-L1) levels and the incidence of adverse reactions were compared between the two groups. Results After treatment, there was no significant difference in objective remission rate and disease control rate between the two groups (P>0.05). After treatment, TCM syndrome scores of cough, phlegm, chest shortness of breath, chest pain, CTC and PD-L1 in study group were significantly lower than those in control group (P<0.05). The incidence of anemia, gastrointestinal adverse reactions and renal damage in study group was significantly lower than that in control group (P<0.05). Conclusion The combination of Peitu Zishen decoction and immunotherapy can improve the TCM syndrome score of patients with advanced NSCLC, and reduce the levels of CTC and PD-L1, as well as the incidence of anemia, gastrointestinal adverse reactions and renal damage.